A phase I study comparing the pharmacokinetics and safety of HS628 (tocilizumab biosimilar) and reference tocilizumab in healthy male subjects

This study aimed to evaluate the pharmacokinetic (PK) similarity of the proposed biosimilar HS628 compared with the reference tocilizumab (Actemra®) and also to demonstrate similar safety and immunogenicity profiles in healthy Chinese male subjects. Eighty eligible subjects were randomized into two...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Hongjie, Cheng, Jie, Gui, Yuzhou, Wang, Wei, Liang, Liyu, Zhu, Huijuan, Wu, Qingqing, Ou, Meixian, Chen, Qian, Yu, Chen, Jia, Jingying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499408/
https://www.ncbi.nlm.nih.gov/pubmed/37403258
http://dx.doi.org/10.1111/cts.13584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499408/
https://www.ncbi.nlm.nih.gov/pubmed/37403258
http://dx.doi.org/10.1111/cts.13584

Ejemplares similares